In first‐line treatment, trastuzumab, pertuzumab, and docetaxel in the CLEOPATRA study greatly extended the OS in patients with breast cancer that is HER2‐positive, with an ORR of 80.2%. Here, ERBB2 is linked to breast carcinoma.